Atrial Fibrillation Ablation Outcomes and Heart Failure (from the Kansai Plus Atrial Fibrillation Registry)
Section snippets
Methods
The KPAF (Kansai Plus Atrial Fibrillation) Registry is a multicenter, observational study, recruiting patients from 26 cardiovascular centers primarily located in the Kansai region of Japan between November 2011 and March 2014 and enrolled 5,010 consecutive patients who underwent a first-time RFCA of AF (UMIN000006127).9 The study protocol was approved by the institutional review board at each participating center.
Vaughan Williams class I or III antiarrhythmic drugs (AADs) were primarily
Results
The baseline characteristics of the total 5,010 enrolled patients divided into those with or without an HF hospitalization after the index RFCA are shown in Table 1. During a 2.92-year mean follow-up, 98 of 5,010 patients (1.96%) experienced a hospitalization for HF after the index RFCA. Patients with HF hospitalizations compared with those without were older (with HF hospitalizations vs without HF hospitalizations, 69.0 ± 10.5 vs 64.3 ± 10.4, respectively, p <0.0001), had a lower body mass
Discussion
The present analysis of the KPAF Ablation Registry of 5,010 patients after the initial RFCA of AF during the 3-year follow-up revealed the following findings: (1) the 3-year cumulative incidence of HF hospitalizations was 1.84% (0.69%/year) after the index RFCA in this real-world registry. (2) AF recurrence was independently associated with HF hospitalizations after the index RFCA (HR 2.84, 95% CI 1.80 to 4.47, p <0.0001) and that was consistent in almost all subgroups, except in the patient
Disclosures
Dr. Inoue has received honoraria from Johnson and Johnson KK and Medtronic, Inc.
Dr. Tanaka has received honoraria from Johnson and Johnson KK. The remaining authors have no conflicts of interest to declare.
Acknowledgment
The authors thank the clinical research coordinators from the study management center for their invaluable help in checking and correcting the enormous data. The authors also thank John Martin, BSc and Danny H.- K. Jokl, MD for their linguistic assistance with the manuscript.
References (26)
- et al.
Causes of death in anticoagulated patients with atrial fibrillation
J Am Coll Cardiol
(2016) - et al.
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Heart Rhythm
(2017) - et al.
Usefulness of failed electrical cardioversion for early recurrence after catheter ablation for atrial fibrillation as a predictor of future recurrence
Am J Cardiol
(2019) - et al.
Cause of very late recurrence of atrial fibrillation or flutter after catheter ablation for atrial fibrillation
Am J Cardiol
(2013) - et al.
Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation
JACC Heart Fail
(2017) - et al.
EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication
Heart Rhythm
(2017) - et al.
Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with catheter ablation in patients with atrial fibrillation and systolic dysfunction: a substudy of the CAMERA MRI trial
JACC Clin Electrophysiol
(2018) - et al.
Usefulness of post-procedural plasma brain natriuretic peptide levels to predict recurrence after catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction
Am J Cardiol
(2021) - et al.
Effect of ablation for atrial fibrillation on heart failure readmission rates
Am J Cardiol
(2017) - et al.
Atrial fibrillation burden and clinical outcomes in heart failure: the CASTLE-AF trial
JACC Clin Electrophysiol
(2021)
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study
Circulation
Atrial fibrillation ablation in heart failure
Eur Heart J
Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades
Eur Heart J
Cited by (1)
This study was supported by the Research Institute for Production Development in Kyoto, Japan.